Literature DB >> 26364608

Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.

C Coarfa1,2, W Fiskus1,3, V K Eedunuri4, K Rajapakshe1, C Foley1,3, S A Chew1,3, S S Shah1,3, C Geng1,3, J Shou3, J S Mohamed3, B W O'Malley1, N Mitsiades1,2,3.   

Abstract

MicroRNAs are important epigenetic regulators of protein expression by triggering degradation of target mRNAs and/or inhibiting their translation. Dysregulation of microRNA expression has been reported in several cancers, including prostate cancer (PC). We comprehensively characterized the proteomic footprint of a panel of 12 microRNAs that are potently suppressed in metastatic PC (SiM-miRNAs: miR-1, miR-133a, miR-133b, miR-135a, miR-143-3p, miR-145-3p, miR-205, miR-221-3p, miR-221-5p, miR-222-3p, miR-24-1-5p, and miR-31) using reverse-phase proteomic arrays. Re-expression of these SiM-miRNAs in PC cells suppressed cell proliferation and targeted key oncogenic pathways, including cell cycle, apoptosis, Akt/mammalian target of rapamycin signaling, metastasis and the androgen receptor (AR) axis. However, only 12%, at most, of these observed protein expression changes could be explained by predicted direct binding of miRNAs to corresponding mRNAs, suggesting that the majority of these proteomic effects result indirectly. AR and its steroid receptor coactivators (SRCs; SRC-1, -2 and -3) were recurrently affected by these SiM-miRNAs. In agreement, we identified inverse correlations between expression of these SiM-miRNAs and early clinical recurrence, as well as with AR transcriptional activity in human PC tissues. We also identified robust induction of miR-135a by androgen and strong direct binding of AR to the miR-135a locus. As miR-135a potently suppresses AR expression, this results in a negative feedback loop that suppresses AR protein expression in an androgen-dependent manner, while de-repressing AR expression upon androgen deprivation. Our results demonstrate that epigenetic silencing of these SiM-miRNAs can result in increased AR axis activity and cell proliferation, thus contributing to disease progression. We further demonstrate that a negative feedback loop involving miR-135a can restore AR expression under androgen-deprivation conditions, thus contributing to the upregulation of AR protein expression in castration-resistant PC. Finally, our unbiased proteomic profiling demonstrates that the majority of actual protein expression changes induced by SiM-miRNAs cannot be explained based on predicted direct interactions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26364608      PMCID: PMC5915337          DOI: 10.1038/onc.2015.295

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  59 in total

1.  Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer.

Authors:  Peter S Nelson
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

2.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.

Authors:  Pei-Chun Lin; Ya-Lin Chiu; Samprit Banerjee; Kyung Park; Juan Miguel Mosquera; Eugenia Giannopoulou; Pedro Alves; Ashutosh K Tewari; Mark B Gerstein; Himisha Beltran; Ari M Melnick; Olivier Elemento; Francesca Demichelis; Mark A Rubin
Journal:  Cancer Res       Date:  2012-12-11       Impact factor: 12.701

3.  Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing.

Authors:  Martin Hart; Elke Nolte; Sven Wach; Jaroslaw Szczyrba; Helge Taubert; Tilman T Rau; Arndt Hartmann; Friedrich A Grässer; Bernd Wullich
Journal:  Mol Cancer Res       Date:  2013-12-13       Impact factor: 5.852

Review 4.  The biological functions of miRNAs: lessons from in vivo studies.

Authors:  Joana A Vidigal; Andrea Ventura
Journal:  Trends Cell Biol       Date:  2014-12-04       Impact factor: 20.808

5.  The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.

Authors:  Tong Sun; Qianben Wang; Steven Balk; Myles Brown; Gwo-Shu Mary Lee; Philip Kantoff
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

6.  Widespread deregulation of microRNA expression in human prostate cancer.

Authors:  M Ozen; C J Creighton; M Ozdemir; M Ittmann
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

7.  miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon.

Authors:  Paolo Gandellini; Marco Folini; Nicole Longoni; Marzia Pennati; Mara Binda; Maurizio Colecchia; Roberto Salvioni; Rosanna Supino; Roberta Moretti; Patrizia Limonta; Riccardo Valdagni; Maria Grazia Daidone; Nadia Zaffaroni
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

8.  MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.

Authors:  Robert S Hudson; Ming Yi; Dominic Esposito; Stephanie K Watkins; Arthur A Hurwitz; Harris G Yfantis; Dong H Lee; James F Borin; Michael J Naslund; Richard B Alexander; Tiffany H Dorsey; Robert M Stephens; Carlo M Croce; Stefan Ambs
Journal:  Nucleic Acids Res       Date:  2011-12-30       Impact factor: 16.971

9.  Ago HITS-CLIP expands understanding of Kaposi's sarcoma-associated herpesvirus miRNA function in primary effusion lymphomas.

Authors:  Irina Haecker; Lauren A Gay; Yajie Yang; Jianhong Hu; Alison M Morse; Lauren M McIntyre; Rolf Renne
Journal:  PLoS Pathog       Date:  2012-08-23       Impact factor: 6.823

Review 10.  One decade of development and evolution of microRNA target prediction algorithms.

Authors:  Paula H Reyes-Herrera; Elisa Ficarra
Journal:  Genomics Proteomics Bioinformatics       Date:  2012-10-23       Impact factor: 7.691

View more
  42 in total

Review 1.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Authors:  Christopher Foley; Nicholas Mitsiades
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

2.  Emerging roles and mechanisms of microRNA‑222‑3p in human cancer (Review).

Authors:  Danhua Wang; Yiwen Sang; Tao Sun; Piaoping Kong; Lingyu Zhang; Yibei Dai; Ying Cao; Zhihua Tao; Weiwei Liu
Journal:  Int J Oncol       Date:  2021-03-24       Impact factor: 5.650

3.  Downregulated miR-31 level associates with poor prognosis of gastric cancer and its restoration suppresses tumor cell malignant phenotypes by inhibiting E2F2.

Authors:  Huaidong Wang; Xiaotian Zhang; Yuxin Liu; Zhaohui Ni; Yan Lin; Zipeng Duan; Yue Shi; Guoqing Wang; Fan Li
Journal:  Oncotarget       Date:  2016-06-14

Review 4.  Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.

Authors:  Vito Cucchiara; Joy C Yang; Vincenzo Mirone; Allen C Gao; Michael G Rosenfeld; Christopher P Evans
Journal:  Cancers (Basel)       Date:  2017-01-16       Impact factor: 6.639

5.  MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.

Authors:  Yang Wang; Ning Shao; Xueying Mao; Minmin Zhu; Weifei Fan; Zhixiang Shen; Rong Xiao; Chuncai Wang; Wenping Bao; Xinyu Xu; Chun Yang; Jian Dong; Deshui Yu; Yan Wu; Caixia Zhu; Liting Wen; Xiaojie Lu; Yong-Jie Lu; Ninghan Feng
Journal:  Oncotarget       Date:  2016-07-26

Review 6.  Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?

Authors:  Zhongwei Zhao; Carsten Stephan; Sabine Weickmann; Monika Jung; Glen Kristiansen; Klaus Jung
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923

7.  MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer.

Authors:  Lei Dai; Yaozong Wang; Liangliang Chen; Jueru Zheng; Jianjun Li; Xianjiang Wu
Journal:  World J Surg Oncol       Date:  2017-01-07       Impact factor: 2.754

8.  The plasma miR-125a, miR-361 and miR-133a are promising novel biomarkers for Late-Onset Hypogonadism.

Authors:  Yao-Ping Chen; Ju Wang; Kai Zhao; Xue-Jun Shang; Hui-Qin Wu; Xing-Rong Qing; Fang Fang; Yan Zhang; Jin Shang; Hong-Gang Li; Hui-Ping Zhang; Huang-Tao Guan; Yuan-Zhong Zhou; Yi-Qun Gu; Wei-Xiong Wu; Cheng-Liang Xiong
Journal:  Sci Rep       Date:  2016-03-22       Impact factor: 4.379

9.  Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients.

Authors:  Romana Urbas; Christian Mayr; Eckhard Klieser; Julia Fuereder; Doris Bach; Stefan Stättner; Florian Primavesi; Tarkan Jaeger; Stefanie Stanzer; Anna Lena Ress; Magdalena Löffelberger; Andrej Wagner; Frieder Berr; Markus Ritter; Martin Pichler; Daniel Neureiter; Tobias Kiesslich
Journal:  Int J Mol Sci       Date:  2016-12-07       Impact factor: 5.923

Review 10.  Molecular determinants of prostate cancer metastasis.

Authors:  Kiera Rycaj; Dean G Tang
Journal:  Oncotarget       Date:  2017-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.